Quantcast
Home > Quotes > CLVS
CLVS

Clovis Oncology, Inc. Common Stock (CLVS) Quote & Summary Data

$16.73
*  
1.29
8.35%
Get CLVS Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading CLVS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
31
Today's High / Low
$ 17.40 / $ 15.22
Share Volume
3,900,100
50 Day Avg. Daily Volume
2,493,526
Previous Close
$ 15.44
52 Week High / Low
$ 69.02 / $ 11.50
Market Cap
881,868,866
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -6.23
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.52

Intraday Chart

Shares Traded

Share Volume:
3,900,100
50 Day Avg. Daily Volume:
2,493,526

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -6.23

Trading Range

The current last sale of $16.73 is 45.48% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 17.40 $ 69.02
 Low: $ 15.22 $ 11.50

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Our marketed product Rubraca┬« (rucaparib) is approved on an accelerated basis in the United States by the Food and Drug Administration ("FDA") as monotherapy for the treatment of patients with deleterious BRCA (human genes associated with the repair of damaged DNA) mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca.  ... More ...  


Risk Grade

Where does CLVS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 15.31
Open Date:
Nov. 16, 2018
Close Price:
$ 15.44
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x